Library that can determine resistance

Genetic screening identifies genes driving resistance with a guide RNA library

Library that can determine resistance

crispr.jpgdoi: 10.1038/nbt.2800
Generation of a mouse genome-wide guide RNA library. Schematic of genetic screening with genome-wide guide RNA libraries.

Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types.

CRISPR technology uses the DNA-cutting enzyme Cas9, with the help of a guide RNA sequence, to find and modify genetic targets. Scientists can easily engineer multiple new guide RNAs using standard molecular biology techniques. This makes for a much faster and efficient method to modify the genome of any cell type in any species.

The team found that a remarkable 50 of 52 guide RNAs tested successfully cut both copies of the genes. The extremely high success rate for these engineered guide RNAs seems to be consistent across many cell types, which led them to create a library of guide RNAs targeting every gene in the mouse genome.

"CRISPR technology is revolutionising how we study the behaviour of cells. We've developed a thorough library that can be used by other researchers to study the role of any gene. We can create a library of this type for any cell or any species."

Dr Kosuke Yusa, lead author from the Wellcome Trust Sanger Institute

The team has engineered a library of nearly 90,000 of these guide RNAs that can be used to target and modify every gene in the mouse genome, and created mutant stem cell libraries. They subjected the mutant libraries to a genetic screen against a bacterial toxin, Clostridium septicum alpha-toxin, to better understand how resistance can occur: This agent has toxic effects on every cell type.

The team targeted 26 genes that are known to be associated with the synthesis of the receptors of this bacterial toxin. They revealed that 17 of these genes were responsible for resistance. Importantly, they also identified previously unknown genes whose mutations confer with resistance to this toxic agent.

"Dr Yusa and his team have used the CRISPR technique in a very innovative and creative way which has allowed them to identify resistance genes for toxins and other agents. This study highlights the power of the technology and illustrates some potential applications it can have."

Professor Allan Bradley, Director Emeritus of the Wellcome Trust Sanger Institute

The team will now use this library to create mutations in cancer cell lines. A major problem with cancer drugs is that often cells can quickly acquire resistance and reject the treatment. By screening for genes that have lost all function through mutation, the team can determine what genes are involved in acquiring resistance to cancer treatments and thus find a clinical target.

Notes to Editors
Publications
  • Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library.

    Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C and Yusa K

    Nature biotechnology 2014;32;3;267-73

Funding

This work was supported by the Wellcome Trust.

Participating Centres
  • Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Chan Zuckerberg Initiative boosts Human Cell Atlas research at the Sanger Institute
Seed Networks projects will focus on specific tissues, such as the thymus, lung, liver, kidney and immune system
Widely-available antibiotics could be used in the treatment of ‘superbug’ MRSA
Genomic analysis shows that a significant number of strains are susceptible to penicillin combined with clavulanic acid
First lung map uncovers new insights into asthma
Understanding lung cells and their signals could help towards finding new asthma drug targets